Medical Device Registration Cost by Country: 2026 Global Comparison

Why Compare Registration Costs Across Countries

Expanding a medical device into international markets is one of the most consequential strategic decisions a manufacturer can make -- and one of the most expensive. A single miscalculation in regulatory budgeting can delay market entry by months or consume margins that took years to build.

Yet most companies still plan country-by-country, relying on fragmented intelligence from consultants, trade associations, or outdated blog posts. Government fees are published publicly, but they tell only a fraction of the story. The total cost of registration includes consulting fees, local representative retainers, document translation, product testing, clinical evidence preparation, and ongoing compliance obligations. Two countries with similar government fees can have total project costs that differ by a factor of five.

This guide provides the first truly comprehensive side-by-side comparison of medical device registration costs across 30+ markets. Every fee figure is sourced from the official fee schedules published by each regulatory authority, supplemented by total cost estimates from regulatory consultancies operating in each market. All dollar amounts are in USD unless otherwise noted. Exchange rates are approximate as of early 2026.

Whether you are a startup planning your first international filing or an established manufacturer optimizing a global registration portfolio, the data below will help you build accurate budgets, prioritize the right markets, and avoid costly surprises.

Quick Comparison Table: Government Fees and Total Costs

The table below summarizes government fees, estimated total project costs, timelines, and registration validity across major markets. "Estimated Total Cost" includes government fees plus typical consulting, local representation, translation, and testing costs for a single Class II equivalent device.

Country	Authority	Device Class	Government Fees	Estimated Total Cost	Timeline	Validity
United States	FDA	510(k) Class II	$26,067 (std) / $6,517 (SB)	$50,000--$150,000	6+ months	No expiration
United States	FDA	PMA Class III	$579,272 (std) / $144,818 (SB)	$500,000--$2M+	12--18+ months	No expiration
United States	FDA	Annual Registration	$11,423	$11,423/year	Annual	Annual renewal
EU	Notified Body	Class I (self-cert)	EUR 750--2,500	$2,000--$5,000	4--6 weeks	Up to 5 years
EU	Notified Body	Class II/III	EUR 3,000--15,000+	$8,000--$50,000+	6--18 months	Up to 5 years
UK	MHRA	All classes	GBP 300/category/year (from April 2026)	$5,000--$15,000	3--6 months	Annual renewal
Brazil	ANVISA	Class I/II (notification)	BRL 1,406 (~$265)	$3,800--$10,000	30 days	10 years
Brazil	ANVISA	Class III/IV (registration)	BRL 8,510--19,856 (~$1,606--$3,747)	$35,000--$142,000	12--24 months	10 years
Japan	PMDA	Class I (Todokede)	Minimal	$5,000--$20,000	Less than 1 month	No expiration
Japan	PMDA	Class II (Ninsho)	~$30,000 avg	$30,000--$80,000	3--6 months	5-year QMS renewal
Japan	PMDA	Class III/IV (Shonin)	$20,000--$120,000	$50,000--$200,000+	6--36 months	No expiration
South Korea	MFDS	Class I	KRW 85,000 (~$73)	$5,000--$15,000	Less than 1 month	No expiration
South Korea	MFDS	Class II	KRW 719,000--1,495,000 (~$617--$1,283)	$20,000--$50,000	4--10 months	No expiration
South Korea	MFDS	Class III/IV	KRW 719,000--1,495,000 (~$617--$1,283)	$30,000--$60,000	6--10 months	No expiration
China	NMPA	Class II (imported)	RMB 210,900 (~$30,000)	$30,000--$80,000	12--24 months	5 years
China	NMPA	Class III (imported)	RMB 308,800 (~$44,000)	$50,000--$150,000	12--36 months	5 years
India	CDSCO	Class A--D	$1,000--$3,000/site	$10,000--$30,000	5--12 months	Perpetual (no expiry)
Saudi Arabia	SFDA	Class A--D	SAR 15,000--23,000 (~$4,000--$6,133)	$15,000--$30,000	35 work days	3 years
Australia	TGA	Class I	AUD 621 (~$416)	$3,000--$8,000	1--5 days	Perpetual
Australia	TGA	Class II/III/IV	AUD 1,187--1,530 + audit fees	$10,000--$50,000	6--12 months	Perpetual
Canada	Health Canada	Class II--IV	CAD 632--30,199	$10,000--$40,000	15 days--15 months	No expiration
Singapore	HSA	Class B	S$1,560--4,460 (~$1,170--$3,350)	$5,000--$15,000	Immediate--160 days	Perpetual
Singapore	HSA	Class C	S$3,900--6,810 (~$2,930--$5,110)	$8,000--$25,000	Immediate--220 days	Perpetual
Singapore	HSA	Class D	S$6,490--12,560 (~$4,870--$9,430)	$15,000--$40,000	180--310 days	Perpetual
Mexico	COFEPRIS	Low Risk	MXN 15,206 (~$800)	$1,000--$2,000	1--3 months	5 years (now 10 per Jan 2026 decree)
Mexico	COFEPRIS	Class II/III	MXN 22,302--28,394 (~$1,100--$1,500)	$5,000--$7,000	3--10 months	5 years (now 10)
Colombia	INVIMA	Class IIb/III (controlled)	~$700--$1,000	$10,000--$25,000	6--8 months	10 years
Vietnam	MoH	Class A--D	VND 500K--6M (~$21--$260)	$6,000--$35,000	3--60 days	Indefinite (Decree 98)

Sources: FDA.gov Federal Register FY2026 fee notice; EU Notified Body published fee lists via European Commission DG SANTE; HSA Singapore official fee schedule (revised July 2024); ANVISA published fee schedules; PMDA user fee appendix; MFDS electronic portal fee tables; NMPA registration fee schedules; CDSCO Medical Devices Rules 2017; SFDA MDMA elevation fees (updated 2025); TGA fees and charges summary (July 2025); Health Canada Fees in Respect of Drugs and Medical Devices Order (2025--2026); COFEPRIS published tariffs 2026; INVIMA registration fee estimates; Vietnam MoH Circular 64/2025 and Notification 645/TB-HTTB. Total cost estimates supplemented by Emergo by UL, Pure Global, Asia Actual, and MedDeviceGuide proprietary research.

United States (FDA)

Government Fees (FY 2026)

The FDA publishes medical device user fees annually via a Federal Register notice. For FY 2026 (October 1, 2025 through September 30, 2026), fees increased approximately 7% over FY 2025 for premarket submissions, while the annual establishment registration fee rose 23% due to a performance improvement adjustment under MDUFA V.

Application Type	Standard Fee	Small Business Fee
Annual Establishment Registration	$11,423	$11,423 (no reduction)
510(k)	$26,067	$6,517
513(g)	$7,820	$3,910
PMA, PDP, PMR, BLA	$579,272	$144,818
De Novo Classification Request	$173,782	$43,446
Panel-track Supplement	$463,418	$115,855
180-Day Supplement	$86,891	$21,723
Real-Time Supplement	$40,549	$10,137
BLA Efficacy Supplement	$579,272	$144,818
30-Day Notice	$9,268	$4,634
Annual Periodic Reporting (Class III)	$20,275	$5,069

Source: Federal Register, "Medical Device User Fee Rates for Fiscal Year 2026," 90 FR 35895 (July 30, 2025).

Small Business Determination: A business (including affiliates) with gross receipts or sales of no more than $100 million qualifies for reduced fees. Businesses with gross receipts of $30 million or less are eligible for a one-time waiver of the first PMA/BLA fee. For FY 2026, the FDA may also waive the annual establishment registration fee for businesses with $1 million or less in gross receipts that can demonstrate financial hardship, such as active bankruptcy -- though this waiver is discretionary and rarely granted.

Total Cost Examples

• 510(k) Class II device: $50,000--$150,000 total, including testing, consulting, and submission preparation. The government fee ($26,067) represents roughly 17--52% of the total.
• PMA Class III device: $500,000--$2M+, with clinical data requirements being the largest cost driver. The government fee ($579,272 standard) can represent 29--100% of the total depending on whether clinical trials are needed.

QMSR: ISO 13485 Now Applies to the US Market

Effective February 2, 2026, the FDA's Quality Management System Regulation (QMSR) replaced the former Quality System Regulation (21 CFR Part 820). The QMSR incorporates ISO 13485:2016 by reference, meaning that for the first time, the US quality system requirements are formally aligned with the international standard used by virtually every other major market. For manufacturers already certified to ISO 13485, this reduces the gap between US and global QMS requirements and strengthens the case for MDSAP participation.

Recommended Reading

The CE + FDA Strategic Combo: How Holding Both Approvals Unlocks 25+ Markets and Cuts Time-to-Market 30-50%

CE Marking 510(k)2026-04-10 · 13 min read

European Union (CE Marking under MDR 2017/745)

Unlike the US, the EU has no central government fee for medical device approval. Instead, costs are driven by Notified Body assessment fees, which vary by NB, device class, and the scope of the conformity assessment.

Notified Body Fees

Notified Bodies charge hourly rates for technical file review, clinical documentation review, QMS audits, and certificate issuance. Based on published fee lists from major NBs (BSI, TUV SUD, DNV, DEKRA, SGS, and others) compiled by the European Commission DG SANTE:

• Technical file review: EUR 200--430 per hour
• Clinical documentation review: EUR 225--545 per hour
• QMS audit: EUR 180--440 per hour per auditor (typically 2 auditors per day)
• Certificate issuance: EUR 100--1,300 per certificate
• Unannounced audits: EUR 2,880--8,925 per audit

For a typical Class IIa device, total NB fees range from EUR 3,000 to 10,000 for initial certification. For Class III devices, NB fees can reach EUR 15,000 or more. These are NB fees only -- they do not include the manufacturer's internal costs, consulting, or clinical evaluation preparation.

Timeline and Capacity

NB capacity constraints remain a significant issue in 2026. Current quoted review timelines are 13--18 months for initial certification, with some NBs reporting backlogs for new applications. Manufacturers should plan 6--18 months from dossier submission to CE certificate issuance, depending on device class and NB availability.

2026 Regulatory Developments

• EUDAMED becomes fully mandatory on May 28, 2026, requiring actor registration, UDI/device registration, and certificate upload across four functional modules.
• The European Commission's MDR/IVDR reform package (COM(2025) 1023) proposes fee reductions of at least 50% for micro-sized manufacturers and 25% for small enterprises, plus the option to defer NB fee payment until conformity assessment is finalized. These amendments are under legislative review as of early 2026.
• CE certificates are valid for up to 5 years, with annual surveillance audits required.

Total Cost Range

Including NB fees, consulting, clinical evaluation, and internal resources, total costs typically range from EUR 5,000 for a simple Class I (self-certified) device to EUR 50,000+ for a Class III device requiring extensive clinical evidence.

United Kingdom (MHRA)

Since Brexit, the MHRA operates a separate registration system from the EU. Manufacturers placing devices on the Great Britain market must register with the MHRA via the Device Online Registration System (DORS).

New Annual Fee Structure (from April 2026)

Effective April 1, 2026, the MHRA replaced its one-time registration fee with an annual fee of GBP 300 per GMDN Level 2 category. This is a fundamental change in how UK registration is funded:

• The fee is calculated based on the number of GMDN Level 2 categories registered as of March 31 each year.
• Multiple devices under the same Level 2 category pay only one annual fee.
• The MHRA estimates that 56% of manufacturers will pay only the minimum GBP 300 annual charge.
• Payments are due within 90 days via DORS. Missed payments result in account suspension and loss of market access.

Manufacturers were required to verify all device registrations by March 30, 2026, and are encouraged to "cleanse" their portfolios by deregistering obsolete devices to minimize fees.

Source: The Medical Devices (Fees Amendment) Regulations 2026 (UK SI 2026/197); MHRA guidance on DORS fee implementation.

Japan (PMDA)

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) operates three registration pathways based on device classification:

Registration Pathways and Costs

1. Todokede (Class I, low risk): Self-declaration with minimal government fees. Total project cost: $5,000--$20,000. Timeline: less than 1 month.

2. Ninsho (Class II, moderate risk): Third-party certification. Government fees average ~$30,000. Total project cost: $30,000--$80,000. Timeline: 3--6 months.

3. Shonin (Class III/IV, high risk): PMDA review. Government fees range from $20,000 to $120,000 depending on classification, clinical evidence requirements, and review complexity. Total project cost: $50,000--$200,000+. Timeline: 6--36 months.

Additional Japan-Specific Costs

• DMAH/MAH (Designated Marketing Authorization Holder): Mandatory for foreign manufacturers. Annual retainer: $15,000--$50,000.
• PMDA consultation meeting: ~$10,000 for a 2-hour clinical evaluation or study consultation.
• QMS inspection: Required for Class II--IV devices, with 5-year renewal.

April 2026: eCTD v4.0 Mandate

Effective April 1, 2026, the PMDA mandates eCTD version 4.0 format for all new drug applications, with medical device submissions expected to follow. Companies submitting in older eCTD v3.2.2 format face rejection. This requires investment in upgraded regulatory information management systems and staff training.

Recommended Reading

CIRCIA Compliance for Medical Device Manufacturers: Preparing for Mandatory Cyber Incident Reporting to CISA

Digital Health & AI Quality Systems2026-05-17 · 13 min read

South Korea (MFDS)

Government Fees

South Korea has some of the lowest government registration fees among major markets:

Review Type	Processing Time	Government Fee
Class I (Notification)	0 days	KRW 85,000 (~$73)
Class II with Substantial Equivalence	25 days	KRW 130,000 (~$112)
Class III/IV with Substantial Equivalence	65 days	KRW 719,000 (~$617)
Class II/III/IV without Substantial Equivalence	80 days	KRW 1,495,000 (~$1,283)

Source: MFDS electronic portal fee tables; Global Regulatory Partners fee summary (September 2022, updated for 2025--2026).

Why Total Costs Are Higher Than Fees Suggest

Despite low government fees, total project costs range from $5,000 to $60,000. The reason is KGMP certification (Korea Good Manufacturing Practices), which is mandatory for all Class II--IV devices. KGMP is specific to South Korea -- ISO 13485 certification alone is not sufficient, though the MFDS announced proposed amendments in March 2025 to allow combined KGMP/MDSAP applications, which would reduce duplication for manufacturers already in the MDSAP program.

A Korea License Holder (KLH) is also required for foreign manufacturers, adding $3,000--$10,000 per year in representative fees.

January 2026: Fast-Track for Innovative Devices

The "Market Immediate Entry Medical Technology" system, launched in late 2024, has reduced approval timelines for innovative devices (medical robots, digital therapeutics, AI diagnostics) from up to 490 days down to 80--140 days. Clinical evaluation under this pathway is flexible, accepting international clinical data, prior market experience in advanced countries, and published scientific literature.

Brazil (ANVISA)

Brazil's ANVISA operates a two-track system: notification for Class I/II devices and registration for Class III/IV devices.

Government Fees

Pathway	Government Fee	Notes
Class I/II Notification	BRL 1,406 (~$265)	Per product
Class III/IV Registration (standard family)	BRL 8,510 (~$1,606)	Per product family
Class III/IV Registration (large family)	BRL 19,856 (~$3,747)	Per large product family
BGMP Certification	BRL 72,805 (~$13,737)	Per manufacturer, required for Class III/IV

MDSAP Dramatically Reduces Brazil Costs

MDSAP certification is the single most impactful cost-saving measure for Brazil. Without MDSAP, manufacturers face standalone BGMP audits at BRL 72,805 plus ANVISA inspector travel costs of $10,000--$40,000. With MDSAP, the BGMP certification can be obtained through documentary review in as little as 2 months, and BGMP validity extends from 2 years to 4 years.

Add-On Costs

• INMETRO certification (electrical safety): $4,000--$6,000 per device
• ANATEL certification (wireless/RF): $3,000--$4,000 per device
• Brazilian Registration Holder (BRH): $2,000--$5,000 setup + $1,500--$3,000/year retainer
• Registration validity: 10 years

Source: ANVISA published fee schedules; MedDeviceGuide "Brazil ANVISA Medical Device Cost Breakdown 2026"; Pure Global market data.

India (CDSCO)

India offers some of the most affordable medical device registration fees globally, making it an attractive market for cost-conscious manufacturers targeting a large and growing healthcare market (~$18 billion in 2026, projected to reach $26--50 billion by 2030--2031).

Government Fees

Device Class	Fee per Site	Fee per Device
Class A	$1,000	$50
Class B	$2,000	$1,000
Class C	$3,000	$1,500
Class D	$3,000	$1,500

Source: CDSCO Medical Devices Rules, 2017; Artixio fee summary (February 2026).

Key Requirements

• Indian Authorized Agent (IAA): Mandatory for all foreign manufacturers
• BIS certification: Required for electronic medical devices
• Import License: Form MD-14 application; Form MD-15 license upon approval
• Validity: Perpetual, provided the license retention fee is paid every 5 years
• Timeline: 5--12 months depending on device class and completeness of application

Recommended Reading

USA Medical Device Registration Cost 2026: U.S. Agent Pricing Models, Flat Fee vs Hourly Billing, and 3-Year Cash Flow Comparison

510(k) Reimbursement & Market Access2026-04-24 · 39 min read

China (NMPA)

China has among the highest government registration fees for imported medical devices, reflecting the complexity of the review process and the size of the market.

Government Fees for Imported Devices

Fee Type	Class II (Imported)	Class III (Imported)
Initial Registration	RMB 210,900 (~$30,000)	RMB 308,800 (~$44,000)
Registration Change	RMB 42,000 (~$6,000)	RMB 50,400 (~$7,200)
Renewal (every 5 years)	RMB 40,800 (~$5,800)	RMB 40,800 (~$5,800)
Clinical Trial Application	--	RMB 43,200 (~$6,200)

Source: NMPA fee schedules; CIRS Group fee summary; GVM Medical LLC; Asia Actual.

Key Requirements

• Local agent: Mandatory for all foreign manufacturers
• NMPA-certified laboratory testing: Required for Class II and III devices
• Clinical data: Local clinical trials may be required, particularly for Class III devices without a "same type device" predicate
• Registration validity: 5 years, with renewal required
• NMPA GMP compliance audit: Revised per Announcement No. 107 of 2025, effective November 2026

2026 Regulatory Updates

• The NMPA continues to issue classification catalogue adjustments, with 31 categories updated in 2025 (some down-classified, some up-classified).
• Foreign-invested enterprises in China can now produce imported device registrations domestically under certain conditions (Announcement No. 30, 2025).

Saudi Arabia (SFDA)

Saudi Arabia uses a risk-based classification (Class A through D) with fees denominated in Saudi Riyals (SAR).

MDMA Registration Fees

Device Class	SFDA Fee (SAR)	SFDA Fee (USD, approx.)	Review Period
Class A	SAR 15,000	~$4,000	35 working days
Class B	SAR 19,000	~$5,060	35 working days
Class C	SAR 21,000	~$5,590	35 working days
Class D	SAR 23,000	~$6,130	35 working days
MDMA Renewal	SAR 5,000	~$1,330	--
Minor Update (label/IFU)	SAR 1,100	~$293	--

Source: SFDA MDMA Elevation Fees (official PDF, updated 2025); OMC Medical; Teriaqi.

Key Requirements

• Authorized Representative (AR): Mandatory for all foreign manufacturers, with an annual AR license fee of SAR 2,600 (~$692)
• GHAD System: All MDMA applications submitted electronically
• Validity: 3 years
• MDMA2 Saudi Route: The only valid registration pathway as of 2026 (the former GHTF/MDMA1 route was cancelled in 2021)

Australia (TGA)

Australia's TGA operates a risk-based fee structure with relatively modest application fees but potentially significant conformity assessment costs.

Application Fees (2025--2026)

Device Class	Application Fee (AUD)	Application Fee (USD, approx.)
Class I	AUD 621	~$416
Class IIa/IIb	AUD 1,187	~$795
Class III	AUD 1,530	~$1,025

Application Audit Assessment Fees

Audit Level	Fee (AUD)	Applies To
Level 1	AUD 4,700	Verification of conformity evidence
Level 2	AUD 17,288	In-depth technical review (Class III mandatory)

Annual Charges

Device Class	Annual Fee (AUD)	Annual Fee (USD, approx.)
Class I (other)	AUD 114	~$76
Class I (sterile/measuring)	AUD 828	~$555
Class IIa/IIb	AUD 1,230	~$824
Class III/AIMD	AUD 1,566	~$1,049

Source: TGA fees and charges summary (July 2025); Asia Actual; Pure Global.

MDSAP certification can be leveraged to reduce conformity assessment costs, as TGA recognizes MDSAP audit reports as evidence of compliance.

Recommended Reading

FDA Weight Loss Device Guidance 2026: Premarket Considerations, Clinical Evidence, and Benefit-Risk Framework

Regulatory Clinical Evidence2026-05-17 · 11 min read

Canada (Health Canada)

Medical Device Licence (MDL) Application Fees (2025--2026)

Application Type	Fee (CAD)	Fee (USD, approx.)
Class II licence	CAD 632	~$465
Class III licence	CAD 13,926	~$10,240
Class III licence (near-patient IVD)	CAD 29,664	~$21,800
Class IV licence	CAD 30,199	~$22,190
Right to sell (annual)	CAD 452	~$332
MDEL application/review	CAD 5,426	~$3,990

Source: Health Canada "Fees in Respect of Drugs and Medical Devices Order" (2025--2026 fee tables).

MDSAP Is Mandatory

Since January 2019, MDSAP certification has been mandatory for all Class II--IV medical devices sold in Canada. This replaced the former CMDCAS (Canadian Medical Devices Conformity Assessment System). MDSAP satisfies the QMS requirement, meaning no separate ISO 13485 audit is needed for the Canadian market.

Singapore (HSA)

Singapore's Health Sciences Authority (HSA) offers multiple evaluation routes, with fees varying significantly based on the route selected and device class.

HSA Fees (Revised July 2024)

Registration Route	Class B (SGD)	Class C (SGD)	Class D (SGD)
Application fee	$560	$560	$560
Immediate route	$1,000	$3,340	N/A
Expedited route	N/A	$3,340	$5,930
Abridged route	$2,010	$3,900	$6,250
Full route	$3,900	$6,250	$12,000

Annual Retention Fees

Device Class	Annual Fee (SGD)
Class B	$39
Class C	$67
Class D	$134

Source: HSA official fee schedule (revised July 1, 2024); Cisema; Asia Actual.

Singapore offers immediate registration for devices with reference country approvals (FDA, CE, TGA, Health Canada, PMDA), making it one of the fastest markets for devices already approved in a major jurisdiction.

Southeast Asia Overview

Vietnam

Vietnam offers the lowest government registration fees of any market covered in this guide:

Device Class	Standard Fee	Discounted Fee (50%, through Dec 2026)	Review Time
Class A	VND 1,000,000 (~$43)	VND 500,000 (~$21)	3--5 days
Class B	VND 3,000,000 (~$130)	VND 1,500,000 (~$65)	3--5 days
Class C	VND 6,000,000 (~$260)	VND 3,000,000 (~$130)	10--60 days
Class D	VND 6,000,000 (~$260)	VND 3,000,000 (~$130)	10--60 days

Source: Vietnam MoH Notification No. 645/TB-HTTB (July 2, 2025); MedDeviceGuide Vietnam registration guide.

Key points: All registration numbers are valid indefinitely under Decree 98. The 50% fee discount runs through December 31, 2026. Total project costs (including local representation, consulting, translation, and testing) range from $6,000 to $35,000.

Thailand

Thailand introduced auto-approval for Class 1 devices in February 2025, streamlining market entry for low-risk products.

Indonesia

BPOM and MoH oversee medical device regulation. Indonesia requires its own review regardless of existing CE marking or FDA clearance, meaning that prior approvals cannot be leveraged for an abbreviated pathway.

Philippines

The FDA operates under Circular 2021-002, with the ASEAN Medical Device Directive (AMDD) framework being progressively implemented.

Malaysia

Malaysia's Medical Device Authority (MDA) joined MDSAP in September 2025, allowing manufacturers with existing MDSAP certification to use their audit reports for Malaysian market access without separate QMS inspections.

Latin America Overview

Mexico (COFEPRIS)

• Government fees: MXN 15,206 ($800) for Class I to MXN 28,394 ($1,500) for Class III
• 30-day fast-track: Available since September 2025 for devices with FDA, Health Canada, EU MDR, Swissmedic, or TGA approval (Abbreviated Regulatory Pathway / equivalence route)
• January 2026 decree: Extended registration renewal period from 5 years to up to 10 years; formalized technovigilance requirements (Article 262 Bis)
• Third-party review: Available at $2,000--$4,000 in addition to government fees

Colombia (INVIMA)

• Registration fees: ~$700--$1,000 government fee for controlled devices (Class IIb/III)
• Total project cost: $10,000--$25,000 including representation, translation, and consulting
• Validity: 10 years for medical devices (5 years for Class III IVDs)
• CTD format: Required for technical submissions
• Timeline: 6--8 months

Argentina (ANMAT)

• Timeline: 6--12 months
• IMDRF observer status
• Total cost: $8,000--$20,000

Chile (ISP)

• Fastest registration in the region: 3--6 months
• Indefinite registration validity
• Total cost: $5,000--$15,000

Peru (DIGEMID)

• Timeline: 4--8 months
• 5-year registration renewal
• Total cost: $8,000--$20,000

How to Budget for Multi-Market Registration

The 10--30% Rule

Government fees typically represent only 10--30% of the total project cost. The remaining 70--90% goes to:

1. Regulatory consulting and dossier preparation (25--40% of total)
2. Local representative or license holder fees (15--25%)
3. Translation and localization (5--15%)
4. Product testing and certification (10--20%)
5. Internal staff and project management (10--20%)
6. Clinical evidence preparation (0--40%, highly variable)

Prioritize Markets Strategically

Not all markets are equal in terms of revenue potential versus registration complexity. A practical framework:

1. Tier 1 (highest revenue, highest complexity): US, EU, Japan, China
2. Tier 2 (moderate revenue, moderate complexity): UK, Brazil, Canada, South Korea, Australia
3. Tier 3 (lower revenue, lower complexity): Saudi Arabia, Singapore, India, Mexico, Southeast Asia

Bundle Audits with MDSAP

The Medical Device Single Audit Program (MDSAP) is the single most cost-effective path for multi-market QMS compliance. One MDSAP audit satisfies QMS requirements for five regulatory jurisdictions simultaneously: US FDA, Health Canada, ANVISA (Brazil), PMDA/MHLW (Japan), and TGA (Australia).

According to the 2024 IMDRF Harmonization Report, MDSAP has reduced audit costs by up to 20% for participating firms. For Brazil specifically, MDSAP saves $30,000--$60,000 over 5 years by eliminating standalone BGMP audits and extending BGMP validity from 2 to 4 years.

Effective February 2, 2026, the FDA's QMSR (which incorporates ISO 13485 by reference) further strengthens the case for MDSAP, as the US quality system requirements are now formally aligned with the ISO 13485 foundation of the MDSAP audit model.

Budget for Ongoing Costs

Registration is not a one-time expense. Plan for:

• Annual establishment registrations (FDA: $11,423/year)
• Surveillance audits (EU NB: annual; KGMP: every 3 years)
• Local representative retainers ($1,000--$10,000/year depending on market)
• Annual listing fees (TGA, HSA, MHRA)
• Post-market surveillance and vigilance reporting
• Registration renewals (China: every 5 years; Saudi Arabia: every 3 years; Mexico: every 5--10 years)

Three-Market Budget Example

For a Class II device entering the US, EU, and one Asian market:

Market Combination	Estimated Total Budget
US + EU + Japan	$150,000--$400,000
US + EU + South Korea	$120,000--$300,000
US + EU + Singapore	$100,000--$250,000
US + EU + China	$130,000--$350,000

Key Takeaways

1. The range is staggering. Government fees span from $21 (Vietnam Class A, discounted) to $579,272 (FDA PMA standard). A manufacturer's total registration budget for a single device can range from under $10,000 to over $2 million depending on the market and classification.

2. Government fees are just the tip of the iceberg. In most markets, the government fee represents less than a quarter of the total project cost. Budget for the full ecosystem: consulting, local representation, translation, testing, and clinical evidence.

3. QMSR makes ISO 13485 central to US compliance. With the FDA's QMSR effective February 2026, ISO 13485 is now the foundational quality standard for both the US and global markets. This alignment reduces incremental QMS costs for multi-market manufacturers.

4. MDSAP is the most cost-effective multi-market strategy. One audit covers five countries. For companies targeting more than two MDSAP-recognized markets, the ROI is clear: reduced audit burden, lower per-market QMS costs, and faster market entry in Brazil and Australia where MDSAP reports are directly leveraged.

5. Plan 2--3 year budgets for multi-market expansion. Registration timelines range from days (Vietnam Class A, Singapore immediate route) to 36 months (Japan Shonin with clinical evidence requirements). Budget time and money accordingly, and sequence filings to optimize cash flow.

Frequently Asked Questions

Which country has the lowest medical device registration fees?

Vietnam offers the lowest government fees at approximately $21--$260 (with 50% discount through December 2026). India is also very affordable at $1,000--$3,000 per site. However, remember that government fees represent only a fraction of total project costs -- local representation, translation, and consulting can multiply the total by 5--20x.

Which country has the highest medical device registration fees?

The US FDA has the highest fees by far: $579,272 for a standard PMA submission and $26,067 for a 510(k). Japan's PMDA can also exceed $120,000 in government fees for Shonin (Class III/IV) applications that require clinical evidence consultation and extended review.

Does MDSAP reduce registration costs?

Yes, significantly. For Brazil alone, MDSAP saves $30,000--$60,000 over 5 years by eliminating standalone BGMP audits and extending BGMP certificate validity. For multi-market manufacturers, MDSAP replaces 5 separate QMS audits (US, Canada, Brazil, Japan, Australia) with a single audit cycle, reducing both direct audit fees and internal preparation costs. The 2024 IMDRF Harmonization Report estimates up to 20% cost savings for participating firms.

How much should I budget for 3-market registration?

For a Class II device entering the US, EU, and one Asian market: budget $80,000--$250,000 total depending on the Asian market chosen. Japan and China are the most expensive ($150,000--$400,000 combined). Singapore and South Korea are more moderate ($100,000--$300,000 combined). These estimates include government fees, consulting, local representation, translation, and testing.

Are small business fee reductions available?

The US FDA offers the most significant small business reductions: 510(k) drops from $26,067 to $6,517 (75% reduction), and PMA from $579,272 to $144,818 (75% reduction). Qualification requires gross receipts/sales of $100 million or less including affiliates. Businesses with $30 million or less in gross receipts also qualify for a one-time first PMA/BLA fee waiver. For FY 2026, businesses with $1 million or less in gross receipts may qualify for an annual registration fee waiver if they can demonstrate financial hardship. Other markets (EU NB reform proposals, Health Canada small business reductions) offer more modest fee relief.